Proteasome inhibition in cancer is associated with enhanced tumor targeting by the adeno-associated virus/phage

Molecular Oncology

Volumn 7, Issue 1, 2013, Pages 55-66

  Przystal, Justyna M ^a   Umukoro, Eloho ^a   Stoneham, Charlotte A ^a   Yata, Teerapong ^a   O'Neill, Kevin ^b   Syed, Nelofer ^b   Hajitou, Amin ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Bacteriophage; Combination therapy; Proteasome; RGD; Tumor targeting

Indexed keywords

INTEGRIN; PARVOVIRUS VECTOR; PROTEASOME; PROTEASOME INHIBITOR;

ADENO ASSOCIATED VIRUS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIOPHAGE; CONTROLLED STUDY; EMBRYO; ENZYME INHIBITION; GENE DELIVERY SYSTEM; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; REPORTER GENE; UBIQUITINATION; UPREGULATION; VIRUS CAPSID;

ADENO-ASSOCIATED VIRUS; EUKARYOTA; MAMMALIA; MIRIDAE; MUS;

EID: 84872485133     PISSN: 15747891     EISSN: 18780261     Source Type: Journal    
DOI: 10.1016/j.molonc.2012.08.001     Document Type: Article

References (44)

1. Allen C., Vongpunsawad S., Nakamura T., James C.D., Schroeder M., Cattaneo R., Giannini C., Krempski J., Peng K.W., Goble J.M., Uhm J.H., Russell S.J., Galanis E. Retargeted oncolytic measles strains entering via the EGFRvIII receptor maintain significant antitumor activity against gliomas with increased tumor specificity. Cancer Res. 2006, 66:11840-11850.
2. Braun-Falco M., Eisenried A., Büning H., Ring J. Recombinant adeno-associated virus type 2-mediated gene transfer into human keratinocytes is influenced by both the ubiquitin/proteasome pathway and epidermal growth factor receptor tyrosine kinase. Arch. Dermatol. Res. 2005, 296:528-535.
3. Caron N.J., Quenneville S.P., Tremblay J.P. Endosome disruption enhances the functional nuclear delivery of Tat-fusion proteins. Biochem. Biophys. Res. Commun. 2004, 319:12-20.
4. Chen D., Dou Q.P. The ubiquitin-proteasome system as a prospective molecular target for cancer treatment and prevention. Curr. Protein Pept. Sci. 2010, 11:459-470.
5. Denby L., Nicklin S.A., Baker A.H. Adeno- associated virus (AAV)-7 and -8 poorly transduce vascular endothelia cells and are senstitive to proteasomal degradation. Gene Ther. 2005, 12:1534-1538.
6. Fortuna W., Miedzybrodzki R., Weber-Dabrowska B., Gorski A. Bacteriophage therapy in children: facts and prospects. Med. Sci. Monit. 2008, 14:126-132.
7. Gartel A.L. A new target for proteasome inhibitors: FoxM1. Expert Opin. Investig. Drugs 2010, 19:235-242.
8. Ghosh D., Barry M.A. Selection of muscle-binding peptides from context-specific peptide-presenting phage libraries for adenoviral vector targeting. J. Virol. 2005, 79:13667-13672.
9. Glickman M.H., Ciechanover A. The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction. Physiol. Rev. 2002, 82:373-428.
10. Granot Z., Melamed-Book N., Bahat A., Orly J. Turnover of StAR protein: roles for the proteasome and mitochondrial proteases. Mol. Cell. Endocrinol. 2007, 265-266:51-58.
11. Grimes K.R., Daosukho C., Zhao Y., Meigooni A., St Clair W. Proteasome inhibition improves fractionated radiation treatment against non-small cell lung cancer: an antioxidant connection. Int. J. Oncol. 2005, 27:1047-1052.
12. Groll M., Ditzel L., Löwe J., Stock D., Bochtler M., Bartunik H.D., Huber R. Structure of 20S proteasome from yeast at 2.4 A resolution. Nature 1997, 386:463-471.
13. Hajitou A., Pasqualini R., Arap W. Vascular targeting: recent advances and therapeutic perspectives. Trends Cardiovasc. Med. 2006, 16:80-88.
14. Hajitou A., Trepel M., Lilley C.E., Soghomonyan S., Alauddin M.M., Marini F.C., Restel B.H., Ozawa M.G., Moya C.A., Rangel R., Sun Y., Zaoui K., Schmidt M., von Kalle C., Weitzman M.D., Gelovani J.G., Pasqualini R., Arap W. A hybrid vector for ligand-directed tumor targeting and molecular imaging. Cell 2006, 125:385-398.
15. Hajitou A., Rangel R., Trepel M., Soghomonyan S., Gelovani J.G., Alauddin M.M., Pasqualini R., Arap W. Design and construction of targeted AAVP vectors for mammalian cell transduction. Nat. Protoc. 2007, 2:523-531.
16. Hajitou A., Lev D.C., Hannay J.A., Korchin B., Staquicini F.I., Soghomonyan S., Alauddini M.M., Benjamin R.S., Pollock R.E., Gelovani J.G., Pasqualini R., Arap W. A preclinical model for predicting drug response in soft-tissue sarcoma with targeted AAVP molecular imaging. Proc. Natl. Acad. Sci. U S A 2008, 105:4471-4476.
17. Hajitou A. Targeted systemic gene therapy and molecular imaging of cancer: contribution of the vascular-targeted AAVP vector. Adv. Genet. 2010, 69:65-82.
18. Hood J.D., Bednarski M., Frausto R., Guccione S., Reisfeld R.A., Xiang R., Cheresh D.A. Tumor regression by targeted gene delivery to the neovasculature. Science 2002, 296:2404-2407.
19. Jennings K., Miyamae T., Traister R., Marinov A., Katakura S., Sowders D., Trapnell B., Wilson J.M., Gao G., Hirsch R. Proteasome inhibiton enhances AAV-mediated transgene expression in human synioviocytes invitro and invivo. Mol. Ther. 2005, 12:1534-1538.
20. Kisselev A.F. Joining the army of proteasome inhibitors. Chem. Biol. 2008, 15:419-421.
21. Kisselev A.F., Goldberg A.L. Proteasome inhibitors: from research tools to drug candidates. Chem. Biol. 2001, 8:739-758.
22. Lang L.H. FDA approves use of bacteriophages to be added to meat and poultry products. Gastroenterology 2006, 131:1370-1372.
23. Larocca D., Witte A., Johnson W., Pierce G.F., Baird A. Targeting bacteriophage to mammalian cell surface receptors for gene delivery. Hum. Gene Ther. 1998, 9:2393-2399.
24. Lu M., Dou Q.P., Kitson R.P., Smith D.M., Goldfarb R.H. Differential effects of proteasome inhibitors on cell cycle and apoptotic pathways in human YT and Jurkat cells. J. Cell. Biochem. 2006, 97:122-134.
25. Masdehors P., Merle-Béral H., Maloum K., Omura S., Magdelénat H., Delic J. Deregulation of the ubiquitin system and p53 proteolysis modify the apoptotic response in B-CLL lymphocytes. Blood 2000, 96:269-274.
26. Monahan P.E., Lothrop C.D., Sun J., Hirsch M.L., Kafri T., Kantor B., Sarkar R., Tillson D.M., Elia J.R., Samulski R.J. Proteasome inhibitors enhance gene delivery by AAV virus vectors expressing large genomes in hemophilia mouse and dog models: a strategy for broad clinical application. Mol. Ther. 2010, 18:1907-1916.
27. Mujtaba T., Dou Q.P. Advances in the understanding of mechanisms and therapeutic use of bortezomib. Discov. Med. 2011, 12:471-480.
28. Neumann M., Mackenzie I.R., Cairns N.J., Boyer P.J., Markesbery W.R., Smith C.D., Taylor J.P., Kretzschmar H.A., Kimonis V.E., Forman M.S. TDP-43 in the ubiquitin pathology of frontotemporal dementia with VCP gene mutations. J. Neuropathol. Exp. Neurol. 2007, 66:152-157.
29. Paoloni M.C., Tandle A., Mazcko C., Hanna E., Kachala S., Leblanc A., Newman S., Vail D., Henry C., Thamm D., Sorenmo K., Hajitou A., Pasqualini R., Arap W., Khanna C., Libutti S.K. Launching a novel preclinical infrastructure: comparative oncology trials consortium directed therapeutic targeting of TNFalpha to cancer vasculature. PLoS One 2009, 4:e4972.
30. Park J., Ayyappan V., Bae E.K., Lee C., Kim B.S., Kim B.K., Lee Y.Y., Ahn K.S., Yoon S.S. Curcumin in combination with bortezomib synergistically induced apoptosis in human multiple myeloma U266 cells. Mol. Oncol. 2008, 2:317-326.
31. Poul M., Marks J.D. Targeted gene delivery to mammalian cells by filamentous bacteriophage. J. Mol. Biol. 1999, 288:203-211.
32. Santoni de Sio F.R., Gritti A., Cascio P., Neri M., Sampaolesi M., Galli C., Luban J., Naldini L. Lentiviral vector gene transfer is limited by the proteasome at post entry steps in various types of stem cells. Stem Cells 2008, 26:2142-2152.
33. Souza G.R., Christianson D.R., Staquicini F.I., Ozawa M.G., Snyder E.Y., Sidman R.L., Miller J.H., Arap W., Pasqualini R. Networks of gold nanoparticles and bacteriophage as biological sensors and cell-targeting agents. Proc. Natl. Acad. Sci. U S A 2006, 103:1215-1220.
34. Tanaka T., Nakatani T., Kamitani T. Inhibition of NEDD8-conjugation pathway by novel molecules: potential approaches to anticancer therapy. Mol. Oncol 2012, 6:267-275.
35. Tandle A., Hanna E., Lorang D., Hajitou A., Moya C.A., Pasqualini R., Arap W., Adem A., Starker E., Hewitt S., Libutti S.K. Tumor vasculature-targeted delivery of tumor necrosis factor-alpha. Cancer 2009, 115:128-139.
36. Trepel M., Stoneham C.A., Eleftherohorinou H., Mazarakis N.D., Pasqualini R., Arap W., Hajitou A. A heterotypic bystander effect for tumor cell killing after adeno-associated virus/phage-mediated vascular-targeted suicide gene transfer. Mol. Cancer Ther. 2009, 8:2383-2391.
37. Tsubuki S., Saito Y., Tomioka M., Ito H., Kawashima S. Differential inhibition of calpain and proteasome activities by peptidyl aldehydes of di-leucine and tri-leucine. J. Biochem. 1996, 119:572-576.
38. Vinitsky A., Michaud C., Powers J.C., Orlowski M. Inhibition of the chymotrypsin- like activity of the pituitary multicatalytic proteinase complex. Biochemistry 1992, 31:9421-9428.
39. Volcy K., Dewhurst S. Proteasome inhibitors enhance bacteriophage lambda (λ) mediated gene transfer in mammalian cells. Virology 2009, 384:77.
40. Wu W.K., Cho C.H., Lee C.W., Wu K., Fan D., Yu J., Sung J.J. Proteasome inhibition: a new therapeutic strategy to cancer treatment. Cancer Lett. 2010, 293:15-22.
41. Yan Y.Y., Zheng L.S., Zhang X., Chen L.K., Singh S., Wang F., Zhang J.Y., Liang Y.J., Dai C.L., Gu L.Q., Zeng M.S., Talele T.T., Chen Z.S., Fu L.W. Blockade of Her2/neu binding to Hsp90 by emodin azide methyl anthraquinone derivative induces proteasomal degradation of Her2/neu. Mol. Pharmacol. 2011, 8:1687-1697.
42. Yu G.Y., Lai M.M. The ubiquitin-proteasome system facilitates the transfer of murine coronavirus from endosome to cytoplasm during virus entry. J. Virol. 2005, 79:644-648.
43. Zhang N.H., Song L.B., Wu X.J., Li R.P., Zeng M.S., Zhu X.F., Wan D.S., Liu Q., Zeng Y.X., Zhang X.S. Proteasome inhibitor MG-132 modifies coxsackie and adenovirus receptor expression in colon cancer cell line lovo. Cell Cycle 2008, 7:925-933.
44. Zhu Q., Wani G., Wang Q.E., El-mahdy M., Snapka R.M., Wani A.A. Deubiquitination by proteasome is coordinated with substrate translocation for proteolysis in vivo. Exp. Cell. Res. 2005, 307:436-451.